BIO Price To Sales Ratio vs Capex To Revenue Analysis
| BKYI Stock | USD 0.90 0.02 2.17% |
BIO Key financial indicator trend analysis is way more than just evaluating BIO Key International prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BIO Key International is a good investment. Please check the relationship between BIO Key Price To Sales Ratio and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BIO Key International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Price To Sales Ratio vs Capex To Revenue
Price To Sales Ratio vs Capex To Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BIO Key International Price To Sales Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have totally related.
The correlation between BIO Key's Price To Sales Ratio and Capex To Revenue is 1.0. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of BIO Key International, assuming nothing else is changed. The correlation between historical values of BIO Key's Price To Sales Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of BIO Key International are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Price To Sales Ratio i.e., BIO Key's Price To Sales Ratio and Capex To Revenue go up and down completely randomly.
Correlation Coefficient | 1.0 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing BIO Key International stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on BIO Key sales, a figure that is much harder to manipulate than other BIO Key International multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most indicators from BIO Key's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BIO Key International current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BIO Key International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. The BIO Key's current Tax Provision is estimated to increase to about 128.5 K, while Selling General Administrative is projected to decrease to under 5.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 18K | 30.0K | 218.3K | 207.4K | Depreciation And Amortization | 514.1K | 546.0K | 590.1K | 573.1K |
BIO Key fundamental ratios Correlations
Click cells to compare fundamentals
BIO Key Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BIO Key fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 2.5M | 22.5M | 17.8M | 11.9M | 4.5M | 4.3M | |
| Other Current Liab | 686.9K | 490.9K | 770.4K | 984.5K | 1.2M | 963.2K | |
| Total Current Liabilities | 4.4M | 1.9M | 2.0M | 4.6M | 3.2M | 3.1M | |
| Total Stockholder Equity | (2.3M) | 20.3M | 15.6M | 7.1M | 1.1M | 1.0M | |
| Property Plant And Equipment Net | 662.0K | 569.1K | 323.3K | 304.8K | 257.1K | 226.5K | |
| Net Debt | 2.7M | (16.3M) | (7.5M) | (414.1K) | (146.1K) | (138.8K) | |
| Retained Earnings | (89.7M) | (99.5M) | (104.6M) | (114.8M) | (125.0M) | (118.8M) | |
| Accounts Payable | 919.3K | 244.2K | 427.8K | 1.1M | 1.3M | 667.1K | |
| Cash | 79.0K | 17.0M | 7.8M | 2.6M | 511.4K | 485.8K | |
| Non Current Assets Total | 1.1M | 3.6M | 3.8M | 2.5M | 1.9M | 1.8M | |
| Non Currrent Assets Other | 240.2K | 174.0K | 370.7K | 437.8K | 229.8K | 218.3K | |
| Cash And Short Term Investments | 591.8K | 17.5M | 7.8M | 2.6M | 511.4K | 485.8K | |
| Common Stock Total Equity | 769.0 | 1.4K | 1.4K | 782.0 | 703.8 | 668.61 | |
| Common Stock Shares Outstanding | 98.8K | 261.2K | 432.9K | 450.0K | 560.3K | 391.0K | |
| Liabilities And Stockholders Equity | 2.5M | 22.5M | 17.8M | 11.9M | 4.5M | 4.3M | |
| Inventory | 429.1K | 330.9K | 4.9M | 4.8M | 445.7K | 657.9K | |
| Other Current Assets | 108.4K | 201.5K | 216.0K | 342.7K | 364.2K | 346.0K | |
| Other Stockholder Equity | 87.4M | 119.8M | 120.2M | 122.0M | 126.0M | 132.4M | |
| Total Liab | 4.8M | 2.2M | 2.2M | 4.9M | 3.5M | 4.7M | |
| Property Plant And Equipment Gross | 662.0K | 569.1K | 323.3K | 304.8K | 1.4M | 1.4M | |
| Total Current Assets | 1.4M | 18.9M | 14.0M | 9.4M | 2.6M | 5.0M | |
| Short Term Debt | 2.4M | 466.3K | 177.2K | 2.9M | 176.6K | 167.7K | |
| Common Stock | 1.4K | 782.0 | 786.0 | 919.0 | 103.0 | 97.85 | |
| Net Receivables | 236.9K | 903.5K | 1.1M | 1.6M | 1.3M | 1.6M | |
| Non Current Liabilities Total | 390.5K | 309.2K | 154.3K | 210.0K | 240.1K | 228.1K | |
| Accumulated Other Comprehensive Income | (690.5K) | (772.3K) | 0.0 | (242.6K) | 22.8K | 24.0K | |
| Other Assets | 240.2K | 174.0K | 370.7K | 1.0 | 0.9 | 0.86 | |
| Property Plant Equipment | 148.6K | 662.0K | 569.1K | 323.3K | 371.8K | 240.4K | |
| Current Deferred Revenue | 359.2K | 657.3K | 565.4K | 462.4K | 415.0K | 394.2K | |
| Intangible Assets | 228.2K | 1.6M | 1.3M | 1.8M | 1.4M | 2.6M | |
| Deferred Long Term Liab | 319.2K | 231.5K | 165.3K | 249.0K | 286.4K | 248.3K | |
| Net Tangible Assets | 3.5M | (2.5M) | 17.5M | 13.0M | 14.9M | 15.7M | |
| Capital Surpluse | 80.8M | 85.6M | 87.4M | 119.8M | 137.8M | 88.3M | |
| Net Invested Capital | (29.7K) | 20.6M | 15.6M | 9.1M | 1.4M | 1.3M |
Currently Active Assets on Macroaxis
When determining whether BIO Key International offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BIO Key's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Key International Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Key International Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BIO Key International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Systems Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BIO Key. If investors know BIO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BIO Key listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.66) | Revenue Per Share 6.323 | Quarterly Revenue Growth (0.41) | Return On Assets (0.56) | Return On Equity (4.58) |
The market value of BIO Key International is measured differently than its book value, which is the value of BIO that is recorded on the company's balance sheet. Investors also form their own opinion of BIO Key's value that differs from its market value or its book value, called intrinsic value, which is BIO Key's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BIO Key's market value can be influenced by many factors that don't directly affect BIO Key's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BIO Key's value and its price as these two are different measures arrived at by different means. Investors typically determine if BIO Key is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BIO Key's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.